Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Reiterates Hold on TrueCar

Needham Reiterates Hold on TrueCar

Needham analyst Chris Pierce reiterates TrueCar (NASDAQ:TRUE) with a Hold.

byBenzinga Newsdesk

February 23, 2023

1 minute read

Needham analyst Chris Pierce reiterates TrueCar (NASDAQ:TRUE) with a Hold.

Analyst Ratings

Critical Insights From Realty Income Analyst Ratings: What You Need To Know

By Benzinga Insights

January 10, 5:01 PM

6 analysts have expressed a variety of opinions on Realty Income (NYSE:O) over the past quarter, offering a…

Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development

By Vandana Singh

January 12, 3:41 PM

89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties.

ETNB

Analyst Ratings

Assessing Magnite: Insights From 11 Financial Analysts

By Benzinga Insights

April 19, 2:01 PM

Magnite (NASDAQ:MGNI) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish…

MGNI

Delta Air Lines CEO Says Don’t Think Demand Is Going To Run Out For Extended Period Of Time; Assumption For 2023 Is Based On Flat GDP; Expect $30B Of Travel Spending Next Year

By Benzinga Newsdesk

December 14, 11:24 AM

- Conf Call

DAL

Needham Reiterates Hold on TrueCar

Related Posts

Critical Insights From Realty Income Analyst Ratings: What You Need To Know

Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development

Assessing Magnite: Insights From 11 Financial Analysts

Delta Air Lines CEO Says Don’t Think Demand Is Going To Run Out For Extended Period Of Time; Assumption For 2023 Is Based On Flat GDP; Expect $30B Of Travel Spending Next Year